

Paolo Bernasconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/499215/publications.pdf>

Version: 2024-02-01

84
papers

3,955
citations

257450

24
h-index

118850

62
g-index

84
all docs

84
docs citations

84
times ranked

4127
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 211.e1-211.e9.	1.2	18
2	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	1.2	4
3	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , 2021, 21, 1622-1628.	4.7	35
4	Outcome of Tâ€cellâ€replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	4.1	8
5	Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. <i>Cancers</i> , 2021, 13, 3170.	3.7	6
6	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-<i>versus</i>-host disease prediction after unrelated donor hematopoietic cell transplantation. <i>Haematologica</i> , 2020, 105, e186-e189.	3.5	12
7	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
8	Diagnosing acute encephalitis in patients with hematological disorders: caveats and pitfalls. <i>Journal of NeuroVirology</i> , 2020, 26, 257-263.	2.1	0
9	Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies. <i>Cancers</i> , 2020, 12, 69.	3.7	16
10	Cutaneous relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a clinical and immunophenotype study of seven patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 250-252.	0.8	0
11	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
12	Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	1.3	20
13	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	3.5	23
14	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
15	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018, 93, 615-622.	4.1	8
16	Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 702-709.	1.3	5
17	Endosteal vessel integrity: a new therapeutic goal in acute myeloid leukemia?. <i>Stem Cell Investigation</i> , 2018, 5, 36-36.	3.0	1
18	Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report. <i>Leukemia and Lymphoma</i> , 2017, 58, 2770-2771.	1.3	1

#	ARTICLE	IF	CITATIONS
19	MDS/AML del(11)(q14) Share Common Morphological Features Despite Different Chromosomal Breakpoints. <i>Anticancer Research</i> , 2017, 37, 645-650.	1.1	1
20	Therapeutically targeting <sc>SELF</sc>â€reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?. <i>American Journal of Hematology</i> , 2016, 91, 507-517.	4.1	21
21	Rearrangements of Tyrosine Kinase (TK) Genes in Chronic Myeloproliferative Disorders (CMPD): A FISH Study. <i>Blood</i> , 2016, 128, 5493-5493.	1.4	0
22	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows longâ€term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	4.1	9
23	Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms. <i>Journal of Hematology and Oncology</i> , 2015, 8, 71.	17.0	8
24	Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2015, 170, 826-836.	2.5	23
25	FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells. <i>Cell Reports</i> , 2014, 6, 18-23.	6.4	39
26	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	1.4	162
27	Validation of the new comprehensive cytogenetic scoring system (<sc>NCCSS</sc>) on 630 consecutive de novo <sc>MDS</sc> patients from a single institution. <i>American Journal of Hematology</i> , 2013, 88, 120-129.	4.1	14
28	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene. <i>Journal of Clinical Oncology</i> , 2013, 31, e269-e271.	1.6	47
29	Correlation between burden of 17<sc>P</sc>13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 162, 555-558.	2.5	9
30	Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphaseâ€FISH. <i>Hematological Oncology</i> , 2013, 31, 136-142.	1.7	12
31	Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. <i>Haematologica</i> , 2012, 97, 1272-1277.	3.5	254
32	The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. <i>Cancer</i> , 2012, 118, 5179-5179.	4.1	3
33	Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. <i>Cancer Genetics</i> , 2012, 205, 285-294.	0.4	4
34	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	1.4	110
35	Response and survival of patients with chronic graftâ€versusâ€host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. <i>Transfusion</i> , 2012, 52, 2007-2015.	1.6	42
36	Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement. <i>Annals of Hematology</i> , 2011, 90, 595-597.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Do FISH Lesions Have Any Role in the Pathogenesis and Outcome of Chromosomally Normal MDS?. Blood, 2011, 118, 1472-1472.	1.4	5
38	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	1.4	6
39	Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Annals of Hematology, 2010, 89, 545-551.	1.8	24
40	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at <i>PML</i> and <i>RARA</i> loci. Genes Chromosomes and Cancer, 2010, 49, 726-732.	2.8	32
41	correspondence: <i>BCL3</i> translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance. British Journal of Haematology, 2010, 150, 702-704.	2.5	5
42	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplantation, 2010, 45, 798-800.	2.4	9
43	Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leukemia and Lymphoma, 2010, 51, 236-242.	1.3	19
44	Blast phase of essential thrombocythemia: A single center study. American Journal of Hematology, 2009, 84, 641-644.	4.1	8
45	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009, 114, 4939-4943.	1.4	62
46	Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions—a review. British Journal of Haematology, 2008, 142, 695-708.	2.5	70
47	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008, 93, 1645-1651.	3.5	241
48	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals of Oncology, 2008, 19, 1331-1335.	1.2	40
49	A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood, 2008, 111, 3383-3387.	1.4	108
50	Reduced Intensity Conditioning with Thiotepa and Fludarabine for Allogeneic Transplantation: Evidence for Low Toxicity and Long-Lasting Disease Control in MDS with Low/Intermediate-1 IPSS Score and in AML from MDS in Complete Remission.. Blood, 2008, 112, 3285-3285.	1.4	0
51	Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2007, 25, 3503-3510.	1.6	969
52	World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. British Journal of Haematology, 2007, 137, 193-205.	2.5	93
53	Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine. Annals of Hematology, 2007, 86, 619-622.	1.8	3
54	Bortezomib with High-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.. Blood, 2007, 110, 3595-3595.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Role of the molecular staging and response in the management of follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1018-1022.	1.3	6
56	Targeting ubiquitin in cancers. <i>European Journal of Cancer</i> , 2006, 42, 3095-3102.	2.8	15
57	Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation as a Late Complication of Chronic Graft-versus-Host Disease. <i>Transplantation</i> , 2006, 81, 1087-1092.	1.0	51
58	Clinical Relevance of Cytogenetics in Myelodysplastic Syndromes. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 395-410.	3.8	30
59	ABL1 amplification in T-cell acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 146-150.	1.0	22
60	Leukemic transformation of polycythemia vera. <i>Cancer</i> , 2005, 104, 1032-1036.	4.1	79
61	Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocytopenic onset. <i>Annals of Hematology</i> , 2005, 84, 127-128.	1.8	2
62	Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2005, 23, 7594-7603.	1.6	804
63	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. <i>Oncology</i> , 2005, 68, 146-153.	1.9	12
64	A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.. <i>Blood</i> , 2005, 106, 788-788.	1.4	18
65	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. <i>Blood</i> , 2005, 106, 791-791.	1.4	2
66	The Relationship between the Immunophenotypic Profile and Cytogenetic Abnormalities in Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 4495-4495.	1.4	0
67	Interphase Fluorescence In Situ Hybridisation (iFISH) To Detect Cryptic Chromosome Defects in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL).. <i>Blood</i> , 2005, 106, 3287-3287.	1.4	0
68	Evolution of a True B-Cell Chronic Lymphocytic Leukaemia (B-CLL) in a Diffuse Immunocytoma after Treatment with Fludarabine.. <i>Blood</i> , 2005, 106, 4973-4973.	1.4	0
69	Molecularly Targeted Therapy in Acute Myeloid Leukemia. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 409-422.	3.8	8
70	Survivin Expression in Acute Leukemias and Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2004, 45, 2229-2237.	1.3	31
71	In Acute Promyelocytic Leukemia (APL) with Multiple Relapses Additional Prognostic Information Is Provided by FLT3 and Telomerase (hTERT) Quantitative Real-Time PCR.. <i>Blood</i> , 2004, 104, 4408-4408.	1.4	0
72	Amplification of the ABL Gene in T-Cell Acute Lymphoblastic Leukemia (T-ALL).. <i>Blood</i> , 2004, 104, 1083-1083.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. <i>British Journal of Haematology</i> , 2002, 116, 855-861.	2.5	36
74	Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance. <i>British Journal of Haematology</i> , 2002, 118, 545-549.	2.5	11
75	Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. <i>Leukemia</i> , 2002, 16, 2078-2083.	7.2	35
76	Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. <i>Annals of Hematology</i> , 2001, 80, 267-271.	1.8	3
77	Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. <i>British Journal of Haematology</i> , 1998, 102, 678-683.	2.5	40
78	Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. <i>British Journal of Haematology</i> , 1997, 97, 586-588.	2.5	7
79	Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, S14-S17.	0.7	7
80	Impact of Advanced Age on the Management of Acute Nonlymphocytic Leukemia: A Study of 103 Patients. <i>Acta Haematologica</i> , 1990, 84, 144-148.	1.4	7
81	Interferon alpha-2b as therapy for patients with Ph1-positive chronic myelogenous leukemia. <i>European Journal of Haematology</i> , 1990, 45, 25-28.	2.2	8
82	Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q). <i>Medical and Pediatric Oncology</i> , 1988, 16, 88-94.	1.0	17
83	Trisomy 12 in a case of large cell, immunoblastic, polymorphous non-Hodgkin's lymphoma with IgG κ monoclonal paraprotein. <i>Cancer Genetics and Cytogenetics</i> , 1984, 13, 279-280.	1.0	5
84	Involvement of chromosome No. 20 in a complex Ph1 translocation. <i>Cancer Genetics and Cytogenetics</i> , 1983, 8, 181-182.	1.0	4